Background {#Sec1}
==========

Shivering is a common perioperative complication because of postanesthesia hypothermia \[[@CR1]\]. Spinal anesthesia has impairment of shivering in the block area and greater heat loss than general anesthesia because of abnormal heat loss owing to vasodilatation \[[@CR2], [@CR3]\]. Shivering can cause severe consequences, such as arterial hypoxia and myocardial ischemia by increasing oxygen consumption \[[@CR4], [@CR5]\]. Tramadol is commonly used for the treatment of shivering in clinical practice. However, tramadol can lead to nausea and vomiting which is very distressing for the patient. Therefore, it is necessary to find a better drug with fewer side effects. Dexmedetomidine, an alpha 2-adrenergic agonist, has been confirmed the effect on treatment and prevention of shivering in various surgeries by reducing the shivering threshold \[[@CR6]\].

There are no large-sample clinical trials evaluating the advantages or disadvantages between dexmedetomidine and tramadol on post-spinal anesthesia shivering. Therefore, we conduct a meta-analysis of randomized controlled trials (RCTs) to compare the effect of intravenous dexmedetomidine and tramadol on post-spinal anesthesia shivering.

Methods {#Sec2}
=======

Literature review {#Sec3}
-----------------

Relevant articles were found by searching PubMed, Cochrane library, Web of Science and Google Scholar by two investigators independently. The terms used for searching included: "Dex", "Dexmedetomidine", "Tramadol", "Anesthesia, Spinal", "Injections, Spinal" and "Shivering" through March 2020, without limits. Furthermore, the researchers looked through the references of the relative papers to find additional studies.

Inclusion criteria of studies {#Sec4}
-----------------------------

Inclusion criteria were as follows: 1) the patients underwent an operation under spinal anesthesia or combined spinal and epidural anesthesia; 2) the comparison was between intravenous dexmedetomidine and tramadol about the treatment effect of shivering; 3) the incidence of side effects was reported in both dexmedetomidine and tramadol groups; 4) the study was a RCT. Meeting papers, correspondences and editorials were excluded.

Data extraction {#Sec5}
---------------

Data were collected independently by two researchers, including patient characteristics, types of surgery, anesthetic type, the drugs for spinal anesthesia, doses of the study drugs, shivering degree, efficacy of shivering treatment, incidence of recurrent shivering and adverse effects. Shivering was graded using a four point scale as per Wrench in all included papers \[[@CR7]\]. Any disaccord was further settled by the third researcher.

Evaluation of risk of bias and the study quality {#Sec6}
------------------------------------------------

Two researchers independently evaluated the risk of bias and the qualities of all included studies according to Cochrane Handbook v5.0.2 and 5 point Jadad scale \[[@CR8]\]. Each of the following items of risk of bias was graded as "high risk of bias", "uncertain risk of bias" or "low risk of bias": random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. Disputes were settled by discussion, if necessary, a third investigator helped to make a decision.

Statistical analysis {#Sec7}
--------------------

Review Manager 5.3 (Cochrane Collaboration, Copenhagen, Denmark) was utilized to perform all statistical analyses. For dichotomous data, risk ratio (RR) with 95% confidence interval (CI) was calculated with the Mantel-Haenszel method. Mean difference was used for continuous variables. If there was significant heterogeneity (I^2^ \> 50%), we tried to find possible reasons of heterogeneity, and then sensitivity analysis was performed with fixed effect model.

Results {#Sec8}
=======

Figure [1](#Fig1){ref-type="fig"} showed the flow chart of this meta-analysis. Thirteen studies were included, involving 864 patients (432 received dexmedetomidine and 432 tramadol) \[[@CR9]--[@CR21]\]. The characteristics of the identified clinical trials were displayed in Tables [1](#Tab1){ref-type="table"}. Surgeries were performed under spinal anesthesia in 12 studies \[[@CR9]--[@CR20]\] and under combined spinal and epidural anesthesia in one study \[[@CR21]\]. In the included studies, 7 compared dexmedetomidine with tramadol \[[@CR9]--[@CR15]\] and the other 6 compared dexmedetomidine with tramadol and clonidine \[[@CR16]--[@CR18], [@CR20]\], pethidine \[[@CR21]\] or butorphanol \[[@CR19]\]. Because our study only compared dexmedetomidine with tramadol, clonidine, pethidine and butorphanol were neglected. The risk-of-bias plot was formed utilizing Review Manager 5.3. (Fig. [2](#Fig2){ref-type="fig"}). Fig. 1The flow chart of study selectionTable 1Characteristics of the included studiesAuthor DateDosageStudy typeJadad ScoreSample size D/TPatient characteristics; Surgical settingType of anesthesia; Drug for anesthesiaDefinition of shiveringOutcomesmeasuresKundra2017Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kgRCT550/5018--65 yr, ASA: I-II;Orthopedic, general, or urological surgerySpinal anesthesia; 0.5% bupivacaineGrade 3 or 4①②③④⑤⑥⑦⑧Venkatraman 2016Dexmedetomidine 0.5 μg/kg, tramadol 1 mg/kgRCT530/3018--70 yr, ASA: I-II;No mentionSpinal anesthesia; To achieve sensory level of at least T10Grades 2 to 4①②③⑤⑥⑦⑧Mittal 2014Dexmedetomidine 0.5 μg/kg; tramadol 0.5 mg/kgRCT425/2518--65 yr, ASA: I-II;Lower abdominal, lower limb, orthopaedic and plastic surgeriesSpinal anesthesia; 0.5% heavy bupivacaine 15 mg.Grade 3 or 4①②③④⑤⑥⑦⑧Fern 2015Dexmedetomidine 0.5 μg/kg; tramadol 0.5 mg/kgRCT320/2018--70 yr, ASA: I-II; Elective orthopaedic, gynaecology or general surgeryCombined spinal and epidural anesthesia; 0.5% hyperbaric bupivacaine 15 mg.Grade 3 or 4①②⑥⑦⑧Keerthi 2017Dexmedetomidine 0.5 μg/kg; tramadol 0.5 mg/kgRCT432 /3218--60 yr, ASA: I-II; Lower abdomen and lower limb surgerySpinal anesthesia; 0.5% hyperbaric bupivacaine 2.8 to 3 mlGrades 2 to 4①②③④⑤⑥⑦⑧Ramesh 2019Dexmedetomidine 0.5 μg/kg; tramadol 0.5 mg/kgRCT330/3018--65 yr, ASA: I-II; Elective lower limb surgerySpinal anesthesia; 0.5% hyperbaric bupivacaine 12.5 mgGrade 3 for at least 2 min①②③④⑤⑧Verma 2018Dexmedetomidine 0.5 μg/kg; tramadol 0.5 mg/kgRCT460/6018--65 yr, ASA: I-II; Elective lower limb, lower abdominal, gynaecological procedures, caesarean sectionsSpinal anesthesia; No mentionGrade 3 or 4①②③④⑤⑥⑦⑧Prasad 2018Dexmedetomidine 0.5 μg/kg; tramadol 0.5 mg/kgRCT525/2518--40 yr, ASA: I-II; Caesarean sectionSpinal anesthesia; 0.5% hyperbaric bupivacaineGrade 3 or 4①②③④⑤⑥⑦⑧Kumar 2016Dexmedetomidine 0.6 μg/kg; tramadol 1.0 mg/kgRCT320/2018--60 yr, ASA: I-II; Elective lower abdominal surgeries and lower limb surgeriesSpinal anesthesia; 0.5% hyperbaric bupivacaine 15 mgGrade 3①②③⑥⑦Verma 2016Dexmedetomidine 0.5 μg/kg; tramadol 2 mg/kgRCT430/3018--45 yr, ASA: I-II; Elective abdominal, gynecological and orthopedic surgeriesSpinal anesthesia; 0.5% hyperbaric bupivacaine 15 mgGrades 2 to 4①②③④⑤⑥⑦Singla 2017Dexmedetomidine 0.5 μg/kg; tramadol 0.5 mg/kgRCT450/5018--65 yr, ASA: I-II; Various surgeries under spinal anesthesiaSpinal anesthesia; 0.5% hyperbaric bupivacaine 3--3.6 mlGrades 2 to 4①②③⑥⑦⑧Singh 2016Dexmedetomidine 0.5 μg/kg; tramadol 0.5 mg/kgRCT430/3020--50 yr, ASA: I-II; Elective lower abdominal, lower limb orthopaedic and gynaecological surgeriesSpinal anesthesia; 0.5% hyperbaric bupivacaine 15 mgGrade 3①②③④⑤⑥⑦⑧Aasim 2016Dexmedetomidine 0.5 μg/kg; tramadol 0.5 mg/kgRCT530/3018--65 yr, ASA: I-II; Various surgeries under spinal anesthesiaSpinal anesthesia; 0.5% hyperbaric bupivacaine 15 mgGrade 3①②③④⑤⑥⑦⑧*RCT* randomized controlled trial, *ASA* American Society of Anesthesiologists. ①: Effective rate of shivering treatment, ②: Time to cease shivering, ③: recurrent rate of shivering, ④: the incidence of nausea, ⑤: the incidence of vomiting, ⑥: the incidence of bradycardia, ⑦: the incidence of hypotension, ⑧: sedation scoreFig. 2The risk of bias assessment of the included studies. Note: There was no high risk of bias found in these studies

Effective rate {#Sec9}
--------------

All eligible RCTs reported the effective rate of shivering control \[[@CR9]--[@CR21]\]. The value of I^2^ = 0% indicated no heterogeneity among the included studies. Dexmedetomidine had higher effective rate of shivering control than tramadol (RR =1.03; 95% CI \[1.01, 1.06\], *P* = 0.01, I^2^ = 14%). (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Forest plot for effective rate of shivering. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel

Time to cease shivering {#Sec10}
-----------------------

Twelve included RCTs compared time to cease shivering of dexmedetomidine and tramadol \[[@CR9]--[@CR16], [@CR18]--[@CR21]\]. The random effect model was utilized, because a high heterogeneity was detected (I^2^ = 98%). The result showed that dexmedetomidine was associated with shorter time to cease shivering than tramadol (MD = -2.14; 95%CI \[− 2.79, − 1.49\], *P* \< 0.00001, I^2^ = 98%). (Fig. [4](#Fig4){ref-type="fig"}) Sensitivity analysis was performed for time to cease shivering by excluding single study sequentially, but no source of heterogeneity was detected. Fig. 4Forest plot for time to cease shivering in minutes. Abbreviations: SD, standard deviation; CI, confidence interval; IV, inverse variance

Recurrent rate of shivering {#Sec11}
---------------------------

There were 12 studies reporting the recurrent rate of shivering \[[@CR9]--[@CR20]\]. The value of I^2^ = 0% indicated no heterogeneity. The result of this study indicated that the recurrent rate of shivering of tramadol was significantly higher than that of dexmedetomidine (RR = 0.45; 95%CI \[0.27, 0.73\], *P* = 0.001, I^2^ = 0%). (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Forest plot comparing recurrent rate of shivering. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel

Nausea and vomiting {#Sec12}
-------------------

Ten papers recorded nausea, \[[@CR9]--[@CR13], [@CR15], [@CR18]--[@CR21]\] and 10 recorded vomiting \[[@CR9]--[@CR13], [@CR15], [@CR16], [@CR18]--[@CR20]\]. Four out of 332 patients receiving dexmedetomidine experienced nausea, and 80 out of 332 patients receiving tramadol experienced nausea. There were 342 patients receiving dexmedetomidine (1 with vomiting) and 342 patients receiving tramadol (41 with vomiting). Dexmedetomidine had lower incidences of nausea and vomiting than tramadol (Nausea: RR = 0.10; 95%CI \[0.05, 0.19\], *P* \< 0.00001, I^2^ = 48%; Vomiting: RR = 0.13; 95% CI \[0.06, 0.30\], P \< 0.00001, I^2^ = 0%). (Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}). Fig. 6Forest plot comparing the incidence of nausea. Abbreviations: CI, confidence interval; M-H, Mantel-HaenszelFig. 7Forest plot comparing the incidence of vomiting. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel

Hypotension and bradycardia {#Sec13}
---------------------------

The incidences of hypotension and bradycardia were recorded in all of the included RCTs, but one \[[@CR13]\]. There were 402 patients receiving dexmedetomidine (24 experienced hypotension and 19 had bradycardia) and 402 patients receiving tramadol (9 experienced hypotension and 2 had bradycardia).

Dexmedetomidine was associated with higher incidence of hypotension (RR = 2.50; 95%CI \[1.24, 5.03\], *P* = 0.01, I^2^ = 0%), and bradycardia (RR = 4.78; 95%CI \[1.76, 13.00\], *P* = 0.002, I^2^ = 0%). (Figs. [8](#Fig8){ref-type="fig"} and [9](#Fig9){ref-type="fig"}). Fig. 8Forest plot comparing the incidence of hypotension. Abbreviations: CI, confidence interval; M-H, Mantel-HaenszelFig. 9Forest plot comparing the incidence of bradycardia. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel

Sedation {#Sec14}
--------

Ten studies reported the incidence of sedation which we defined as being drowsy and responding to verbal or physical stimuli \[[@CR9]--[@CR16], [@CR19], [@CR20]\]. The value of I^2^ = 82% indicated high heterogeneity. The incidence of sedation of dexmedetomidine was significantly higher than that of tramadol (RR = 2.48; 95%CI \[1.32, 4.65\], *P* = 0.005, I^2^ = 82%). (Fig. [10](#Fig10){ref-type="fig"}). Fig. 10Forest plot comparing the incidence of sedation. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel

Sensitivity analysis was performed for the incidence of sedation by excluding single study sequentially, but no source of high heterogeneity was detected. There were no patients with over sedation reported in the included studies. Over sedation was defined as no response to physical stimuli.

Publication bias {#Sec15}
----------------

Figure [11](#Fig11){ref-type="fig"} showed that no publication bias was detected for recurrent rate of shivering. Fig. 11Funnel plot of recurrent rate of shivering

Discussion {#Sec16}
==========

In this meta-analysis, we compare the efficacy of intravenous dexmedetomidine and tramadol on the treatment of shivering after spinal anesthesia in adult patients. Dexmedetomidine is associated with higher effective rate of shivering control, shorter time to cease shivering, lesser recurrence of shivering, lower incidences of nausea and vomiting, higher incidences of hypotension, bradycardia and sedation than tramadol.

In this meta-analysis, dexmedetomidine has shorter time to cease shivering and a higher incidence of sedation than tramadol. But these outcomes have high heterogeneities, which are possibly associated with the following: 1) Inclusion criteria for shivering degree are different among the included studies, shivering degrees of 2 to 4 are included in 4 RCTs \[[@CR14], [@CR16], [@CR18], [@CR19]\] and shivering degrees of 3 or 4 in the other 9 RCTs \[[@CR9]--[@CR13], [@CR15], [@CR17], [@CR20], [@CR21]\]. 2) The types and doses of local anesthetics for spinal anesthesia are different among the studies; 3) The types and duration of the surgeries are different.

In this study, tramadol is associated with significantly higher incidences of nausea and vomiting than dexmedetomidine. Nausea and vomiting is very distressing for the patient. Moreover, vomiting may cause rare but serious consequences, such as aspiration, esophageal rupture, subcutaneous emphysema or pneumothorax \[[@CR22]\]. However, dexmedetomidine has significantly higher incidences of hypotension and bradycardia compared to tramadol. Dexmedetomidine has an inherent property of postsynaptic activation of alpha 2-adrenoceptors in the central nervous system to decrease heart rate and blood pressure. We can't assess the clinically significance of hypotension and bradycardia, because of lack of research data.

Tramadol is a well-established agent in treatment of shivering. The mechanism of anti-shivering action of tramadol may be its opioid or serotonergic and noradrenergic activity or both \[[@CR23]--[@CR25]\]. Dexmedetomidine, an alpha-2 adrenoceptor agonist, has antihypertensive, sedative, analgesic and anti-shivering properties \[[@CR26]\]. The anti-shivering effects of alpha adrenoceptor agonists are mediated by binding to alpha receptors that mediate the vasoconstriction. In addition, it has hypothalamic thermoregulatory effects of reducing the vasoconstriction and shivering thresholds \[[@CR27]\]. It suggests that dexmedetomidine acts on the central thermoregulatory system rather than preventing shivering peripherally \[[@CR28]\]. The effect of dexmedetomidine on treatment of shivering has been confirmed in the previous studies \[[@CR29]--[@CR31]\]. Dexmedetomidine and tramadol are not only effective for shivering treatment, but also effective for shivering prevention \[[@CR32]--[@CR34]\].

The sedation achieved is better in patients receiving dexmedetomidine than patients receiving tramadol. None of patients experiencing over sedation or respiratory depression is reported in the included studies \[[@CR9]--[@CR21]\]. Since the surgery is done under spinal anesthesia, the sedation seen with dexmedetomidine is beneficial for the surgeon, anesthetist as well as the patient, because it provides comfort and amnesia to the patient, cardiorespiratory stability and good surgical conditions during surgery. Therefore, dexmedetomidine may be a good choice for shivering control after spinal anesthesia because of its dual effects of anti-shivering and sedation.

There are two limitations in this study. First of all, there is a high heterogeneity regarding time to cease shivering and the incidence of sedation. Secondly, intravenous dexmedetomidine causes hypotension and bradycardia, but we haven't analyzed whether it is clinically significant, due to lack of research data. Therefore, more RCTs are required for further study.

Conclusions {#Sec17}
===========

Dexmedetomidine is superior to tramadol for shivering treatment, due to higher effective rate of shivering control, earlier onset of action and lesser recurrence of shivering with higher incidence of sedation and lower incidences of nausea and vomiting. However, dexmedetomidine is also associated with higher incidences of hypotension and bradycardia than tramadol.
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